# Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

> **NCT01379469** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 20 (actual)

## Conditions studied

- Alpha-1-antitrypsin Deficiency
- Liver Cirrhosis

## Interventions

- **DRUG:** Drug-Carbamazepine (Tegretol XR)
- **DRUG:** Carbamazepine (Tegretol XR) Placebo

## Key facts

- **NCT ID:** NCT01379469
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-10-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01379469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01379469, "Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01379469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*